News

Alagille syndrome comes with a high clinical, economic, and quality-of-life burden for patients and their families, but new treatments such as Livmarli (maralixibat)…

Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CNP-104, Cour Pharmaceuticals’ treatment candidate for primary biliary cholangitis (PBC).

Enrollment is ongoing in a Phase 3 clinical trial that’s designed to evaluate Mirum Pharmaceuticals’ maralixibat for treatment-resistant itching, or pruritus, associated with rare…

Biochemical crosstalk between the body’s own cells and microbes living in the intestines helps regulate the accumulation of fat in the liver, a new study…

A robotic-assisted Kasai surgical procedure results in less blood loss, faster bowel function recovery, and greater rates of clearing jaundice at three and six…

Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…

Liver transplants from a living donor may mean a lower success and a higher need for a second transplant relative to those from a deceased…

A combination of two new mutations in the TJP2 gene was identified as the cause of a mild form of progressive familial intrahepatic cholestasis type 4 (PFIC4) in…

A molecular system controlled by a protein called FBP1 is responsible for how liver cells damaged by MASH — fully, metabolic dysfunction-associated steatohepatitis, a severe…